Prelude Therapeutics Inc Cash Flow-to-Debt Ratio
Prelude Therapeutics Inc cash flow-to-debt ratio. Prelude Therapeutics Inc (PRLD) has a Cash Flow-to-Debt Ratio of -0.53x as of September 2025, meaning its operating cash flow of $-19.11 Million could theoretically repay -1% of its total liabilities ($36.22 Million) in one year. See PRLD financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Prelude Therapeutics Inc (2018–2024)
Cash flow-to-debt ratio of Prelude Therapeutics Inc from 2018 to 2024. Historical debt coverage capacity for Prelude Therapeutics Inc across 7 annual periods. Also explore PRLD year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Prelude Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2024)
Prelude Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2024. Year-by-year debt coverage analysis for Prelude Therapeutics Inc. For the full cash flow conversion analysis, see PRLD cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.34x | $-102.89 Million | $44.06 Million | ▲ +11.5% |
| 2023 | -2.64x | $-107.06 Million | $40.58 Million | ▲ +21.0% |
| 2022 | -3.34x | $-83.73 Million | $25.06 Million | ▲ +23.2% |
| 2021 | -4.35x | $-83.53 Million | $19.20 Million | ▼ -7.5% |
| 2020 | -4.05x | $-46.18 Million | $11.41 Million | ▼ -1024.3% |
| 2019 | -0.36x | $-25.66 Million | $71.28 Million | ▼ -8.7% |
| 2018 | -0.33x | $-12.95 Million | $39.10 Million | — |